FDA to Expedite Review of Some Generics

The announced change to its policy on how the agency prioritizes its review of generic drug applications means FDA will expedite the review of generic drug applications until there are three approved generics for a given drug product.

The U.S. Food and Drug Administration implemented a new policy on June 27 to expedite the review of generic drug applications where competition is limited and also published a list of off-patent, off-exclusivity branded drugs without approved generics. These actions are among the first taken under the agency's Drug Competition Action Plan announced by FDA Commissioner Dr. Scott Gottlieb in May 2017. "No patient should be priced out of the medicines they need, and as an agency dedicated to promoting public health, we must do our part to help patients get access to the treatments they require," he said. "Getting safe and effective generic products to market in an efficient way, being risk-based in our own work, and making sure our rules aren't used to create obstacles to new competition can all help make sure that patients have access to more lower-cost options."

To encourage generic drug development, FDA posted a list of branded drugs that have no listed patents or exclusivities and for which the agency has yet to approve a generic drug application and said it will expedite review of any generic drug application for a product on that list to ensure they come to market as quickly as possible. The announced change to its policy on how the agency prioritizes its review of generic drug applications means FDA will expedite the review of generic drug applications until there are three approved generics for a given drug product.

The actions follow FDA's announcement of a public meeting on July 18, 2017, to solicit input on places where its rules are being used in ways that may create obstacles to generic access. "I am committed to continuing to pursue additional policy steps, under the FDA's current authority, to help reduce the burden on patients who have a difficult time paying for the medicines they need," Gottlieb said.

Product Showcase

  • Glove Guard® Clip

    Safety should never be compromised, especially when it comes to proper glove usage. The Glove Guard® clip enhances safety by encouraging employees to keep their gloves with them at all times. This reduces the risk of accidents and injuries on the job. By ensuring everyone has their gloves readily available, we help promote a culture of safety and efficiency. The Glove Guard® clip is designed to withstand the toughest work environments. Constructed from robust materials made in the USA, it can endure extreme conditions, including harsh weather, and rigorous activities. Read More

  • Preventative Heat Safety

    Dehydration and heat exposure impair physical and cognitive performance. Proper hydration boosts heat stress resilience, but hydration needs are highly individualized and hard to predict across a workforce. Connected Hydration® empowers industrial athletes to stay safe through behavioral interventions, informed by sports science, and equips safety teams with critical insights to anticipate high-risk situations and adapt to evolving environmental factors. Curious about applying the latest in sports science based hydration strategies for industrial athletes? Stop by booth #1112 at AIHA or schedule a free demo today at https://epcr.cc/demo. Read More

  • Magid® D-ROC® GPD412 21G Ultra-Thin Polyurethane Palm Coated Work Gloves

    Magid’s 21G line is more than just a 21-gauge glove, it’s a revolutionary knitting technology paired with an advanced selection of innovative fibers to create the ultimate in lightweight cut protection. The latest offering in our 21G line provides ANSI A4 cut resistance with unparalleled dexterity and extreme comfort that no other 21-gauge glove on the market can offer! Read More

Featured